Development of functionally selective agonists as novel therapeutic agents

Kelly A. Berg; William P. Clarke

doi:10.1016/j.ddstr.2006.10.017

Development of functionally selective agonists as novel therapeutic agents

Kelly A. Berg, William P. Clarke

Department of Pharmacology

Research output: Contribution to journal › Review article › peer-review

24 Scopus citations

Abstract

Traditionally, drug selectivity has been attributed solely to differential affinity for different receptor subtypes. Recent experimental evidence suggests that, in addition to receptor subtype selectivity, drugs may be selective for individual signaling pathways coupled to a single receptor subtype. This 'functional selectivity' holds the promise of improved therapeutic selectivity and reduced adverse effects.

Original language	English (US)
Pages (from-to)	421-428
Number of pages	8
Journal	Drug Discovery Today: Therapeutic Strategies
Volume	3
Issue number	4
DOIs	https://doi.org/10.1016/j.ddstr.2006.10.017
State	Published - Jun 2006

ASJC Scopus subject areas

Molecular Medicine
Pharmacology
Drug Discovery

Access to Document

10.1016/j.ddstr.2006.10.017

Cite this

@article{21d7407545c54a629a797ccd666ba323,

title = "Development of functionally selective agonists as novel therapeutic agents",

abstract = "Traditionally, drug selectivity has been attributed solely to differential affinity for different receptor subtypes. Recent experimental evidence suggests that, in addition to receptor subtype selectivity, drugs may be selective for individual signaling pathways coupled to a single receptor subtype. This 'functional selectivity' holds the promise of improved therapeutic selectivity and reduced adverse effects.",

author = "Berg, {Kelly A.} and Clarke, {William P.}",

year = "2006",

month = jun,

doi = "10.1016/j.ddstr.2006.10.017",

language = "English (US)",

volume = "3",

pages = "421--428",

journal = "Drug Discovery Today: Therapeutic Strategies",

issn = "1740-6773",

publisher = "Elsevier Ltd",

number = "4",

}

TY - JOUR

T1 - Development of functionally selective agonists as novel therapeutic agents

AU - Berg, Kelly A.

AU - Clarke, William P.

PY - 2006/6

Y1 - 2006/6

N2 - Traditionally, drug selectivity has been attributed solely to differential affinity for different receptor subtypes. Recent experimental evidence suggests that, in addition to receptor subtype selectivity, drugs may be selective for individual signaling pathways coupled to a single receptor subtype. This 'functional selectivity' holds the promise of improved therapeutic selectivity and reduced adverse effects.

AB - Traditionally, drug selectivity has been attributed solely to differential affinity for different receptor subtypes. Recent experimental evidence suggests that, in addition to receptor subtype selectivity, drugs may be selective for individual signaling pathways coupled to a single receptor subtype. This 'functional selectivity' holds the promise of improved therapeutic selectivity and reduced adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=33846211115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846211115&partnerID=8YFLogxK

U2 - 10.1016/j.ddstr.2006.10.017

DO - 10.1016/j.ddstr.2006.10.017

M3 - Review article

AN - SCOPUS:33846211115

SN - 1740-6773

VL - 3

SP - 421

EP - 428

JO - Drug Discovery Today: Therapeutic Strategies

JF - Drug Discovery Today: Therapeutic Strategies

IS - 4

ER -

Development of functionally selective agonists as novel therapeutic agents

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this